JP2021514967A5 - - Google Patents

Download PDF

Info

Publication number
JP2021514967A5
JP2021514967A5 JP2020544744A JP2020544744A JP2021514967A5 JP 2021514967 A5 JP2021514967 A5 JP 2021514967A5 JP 2020544744 A JP2020544744 A JP 2020544744A JP 2020544744 A JP2020544744 A JP 2020544744A JP 2021514967 A5 JP2021514967 A5 JP 2021514967A5
Authority
JP
Japan
Prior art keywords
compound
formula
crystal type
crystal
spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544744A
Other languages
English (en)
Japanese (ja)
Other versions
JP7031002B2 (ja
JP2021514967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/076916 external-priority patent/WO2019170067A1/zh
Publication of JP2021514967A publication Critical patent/JP2021514967A/ja
Publication of JP2021514967A5 publication Critical patent/JP2021514967A5/ja
Application granted granted Critical
Publication of JP7031002B2 publication Critical patent/JP7031002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544744A 2018-03-05 2019-03-05 ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法 Active JP7031002B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810180641.8 2018-03-05
CN201810180641 2018-03-05
PCT/CN2019/076916 WO2019170067A1 (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Publications (3)

Publication Number Publication Date
JP2021514967A JP2021514967A (ja) 2021-06-17
JP2021514967A5 true JP2021514967A5 (enExample) 2021-07-29
JP7031002B2 JP7031002B2 (ja) 2022-03-07

Family

ID=67846865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544744A Active JP7031002B2 (ja) 2018-03-05 2019-03-05 ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法

Country Status (11)

Country Link
US (1) US11535613B2 (enExample)
EP (1) EP3763713A4 (enExample)
JP (1) JP7031002B2 (enExample)
KR (1) KR102484804B1 (enExample)
CN (1) CN111819177B (enExample)
AU (1) AU2019230497B2 (enExample)
CA (1) CA3092315C (enExample)
NZ (1) NZ767352A (enExample)
RU (1) RU2769050C1 (enExample)
TW (1) TWI794433B (enExample)
WO (1) WO2019170067A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136319B2 (en) * 2016-09-05 2021-10-05 Guangdong Raynovent Biotech Co., Ltd. Anti-influenza virus pyrimidine derivative
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
CN116323593B (zh) * 2020-10-29 2025-06-03 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
CN120865213A (zh) * 2021-02-03 2025-10-31 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
US20240208908A1 (en) * 2021-03-11 2024-06-27 Shanghai Jemincare Pharmaceutical Co., Ltd Crystal form of pyridine nitrogen oxide compound and use thereof
WO2025237212A1 (zh) * 2024-05-11 2025-11-20 广东众生睿创生物科技有限公司 一种嘧啶衍生物葡甲胺盐及其晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101903354B1 (ko) * 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
EP2651940A1 (en) * 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2012097273A1 (en) * 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
KR102488479B1 (ko) * 2014-08-08 2023-01-12 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 인플루엔자 바이러스 감염에 사용하기 위한 인돌
CN109748915B (zh) * 2015-12-09 2021-03-26 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
EP3426900A4 (en) * 2016-03-07 2019-12-11 Hytech Power, Inc. Method for producing and distributing a second fuel for a combustion engine
US11136319B2 (en) * 2016-09-05 2021-10-05 Guangdong Raynovent Biotech Co., Ltd. Anti-influenza virus pyrimidine derivative

Similar Documents

Publication Publication Date Title
JP2021514967A5 (enExample)
JPWO2022138987A5 (enExample)
JP2021530565A5 (enExample)
JP2023082086A5 (enExample)
JP2020512316A5 (enExample)
JP2007532560A5 (enExample)
JP2008520742A5 (enExample)
JP2018024682A5 (enExample)
JP2016510323A5 (enExample)
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
JP2007519721A5 (enExample)
JP2012530765A5 (enExample)
JP2012533550A5 (enExample)
JP2018502135A5 (enExample)
AU2017303898A1 (en) Production method for pyrazole-amide compound
CN111386268A (zh) 一种urat1抑制剂的晶型及其制备方法
RU2015113277A (ru) Кристаллическтие соединения
JP2011500575A5 (enExample)
JP2015531354A5 (enExample)
RU2015114085A (ru) Кристаллические формы производных дигидропиримидина
RU2019138773A (ru) Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций
JP2020517676A5 (enExample)
JP2017528485A5 (enExample)
CN104610195A (zh) 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JP2018509421A5 (enExample)